MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Slēgts

SektorsVeselības aprūpe

2.74 -0.72

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.68

Max

2.76

Galvenie mērījumi
By Trading Economics
Ienākumi	-24M -16M
Pārdošana	30M 112M
P/E Sektora vidējais	132 63.808
EPS	0.01
Peļņas marža	-14.245
Darbinieki	591
EBITDA	-20M -2.5M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+160.29% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-742M 815M
Iepriekšējā atvēršanas cena	3.46
Iepriekšējā slēgšanas cena	2.74

Ziņu noskaņojums

By Acuity

43%

57%

138 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

4.079 / 4.323 Atbalsts un pretestība

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. apr. 23:26 UTC

Karstas akcijas

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026. g. 16. apr. 20:41 UTC

Galvenie tirgus virzītāji

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026. g. 16. apr. 23:49 UTC

Tirgus saruna

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026. g. 16. apr. 23:45 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record High -- Market Talk

2026. g. 16. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 16. apr. 22:51 UTC

Tirgus saruna

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026. g. 16. apr. 22:08 UTC

Peļņas

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Peļņas

Health Care Roundup: Market Talk

2026. g. 16. apr. 20:49 UTC

Peļņas

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026. g. 16. apr. 20:43 UTC

Peļņas

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026. g. 16. apr. 20:40 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 16. apr. 20:40 UTC

Tirgus saruna

Peļņas

Netflix Says Engagement Quality Hits New High -- Market Talk

2026. g. 16. apr. 20:30 UTC

Karstas akcijas

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026. g. 16. apr. 20:25 UTC

Peļņas

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026. g. 16. apr. 20:23 UTC

Peļņas

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026. g. 16. apr. 20:19 UTC

Peļņas

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026. g. 16. apr. 20:17 UTC

Peļņas

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026. g. 16. apr. 20:17 UTC

Peļņas

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

160.29% augšup

Prognoze 12 mēnešiem

Vidējais 7.21 USD 160.29%

Augstākais 10 USD

Zemākais 3.5 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

138 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.